VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | Treatment strategies for HER2+ metastatic breast cancer

Rupert Bartsch, MD, Medical University Vienna, Vienna, Austria, gives an overview of the current standard of care treatments for patients with HER2-positive metastatic breast cancer, highlighting key studies that led to their approval. First-line treatment consists of taxane plus pertuzumab or trastuzumab and the preferred second-line treatment is ado-trastuzumab emtansine (T-DM1). Whilst third-line treatments are less well defined, patients are either treated with a combination of tucatinib, trastuzumab and capecitabine, or with an antibody-drug conjugate (ADC). Recently, the Phase 3 DESTINY-Breast03 trial (NCT03529110) showed a significantly improved progression-free survival (PFS) for patients treated with trastuzumab deruxtecan (T-DXd) over patients treated with T-DM1 as a second-line treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.


Dr Bartsch reports an advisory role for Astra-Zeneca, Daiichi, Eisai, Eli-Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Puma, Roche, Seagen.

Dr Bartsch reports lecture honoraria for Astra-Zeneca, Celgene, Eli-Lilly, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen.

Dr Bartsch reports research support for Daiichi, MSD, Novartis, Roche.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter